Pharmacokinetics of levetiracetam and its enantiomer (R)-α-ethyl-2-oxo-pyrrolidine acetamide in dogs

Epilepsia

Volumn 42, Issue 7, 2001, Pages 825-830

  Isoherranen, Nina ^a   Yagen, Boris ^a,d   Soback, Stefan ^b   Roeder, Michael ^c   Schurig, Volker ^c   Bialer, Meir ^a,d,e  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b KIMRON VETERINARY INSTITUTE   (Israel)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d David R Bloom Center for Pharmacy   (Israel)

^e HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Antiepileptic; Enantioselective pharmacokinetics; Levetiracetam; Renal clearance

Indexed keywords

ALPHA ETHYL 2 OXOPYRROLIDINE ACETAMIDE; ETIRACETAM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTICONVULSANT ACTIVITY; ARTICLE; DOG; DRUG CLEARANCE; DRUG POTENCY; DRUG SYNTHESIS; EPILEPSY; KIDNEY CLEARANCE; MALE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTICONVULSANTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; HALF-LIFE; MALE; PIRACETAM; STEREOISOMERISM;

EID: 0034849129     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1528-1157.2001.042007825.x     Document Type: Article

References (30)

1. The new wave of anticonvulsant: Focus on levetiracetam oxcarbazepine and zonisamide
2. Piracetam in the treatment of myoclonus: An overview
3. Levetiracetam
4. Profile of ucb LO59, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats
5. ucb LO59, a novel anticonvulsant drug: Pharmacological profile in animals
6. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb LO59) in the kindling model of temporal lobe epilepsy
7. Pharmacokinetic profile of levetiracetam: Toward ideal characteristics
8. Progress report on new antiepileptic drugs: A summary of the fourth Eilat conference (EILAT IV)
9. Clinical pharmacokinetics of new antiepileptic drugs
10. Drug chirality and its clinical significance
11. Role of pharmacokinetics and metabolism in drug discovery and development
12. Comparative pharmacokinetics of the newer antiepileptic drugs
13. Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin
14. Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects
15. Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide
16. Racemization kinetics of enantiomeric oxazepams and stereoselective hydrolysis of enantiomeric oxazepam acetates in rat liver microsomes and brain homogenate
17. Mechanistic studies on the metabolic chiral inversion of R-ibuprofen in the rat
18. Enantioselective analysis of levetiracetam and its enantiomer R-alpha-ethyl-2-oxopyrrolidine acetamide using gas chromatography and ion trap mass spectrometric detection
19. Species similarities and differences in pharmacokinetics
20. Physiological parameters in laboratory animals and humans
21. Stereoselectivity in pharmacokinetics: A general theory
22. Stereoselective disposition of racemic E-10-hydroxynortriptyline in human beings
23. Enantioselective disposition of ofloxacin in humans
24. Enantioselective disposition of salbutamol in man following oral and intravenous administration
25. Aging effects on the organic base transporter and stereoselective renal clearance
26. Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb LO59) in the rat
27. Clinical pharmacology of valpromide
28. Pharmacokinetic evaluation of the structural requirements for a stable valpromide analog
29. Can we develop improved derivatives of valproic acid?